Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,558 questions in 115 reviews · Vascular
current versionsNo studies 346 · 22.2%Ungraded 90 · 5.8%Very low 281 · 18%Low 477 · 30.6%Moderate 313 · 20.1%High 51 · 3.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR Complete clot lysis (intermediate, 6 months to under 5 years after treatment) · patients diagnosed with acute DVT Thrombolytic strategies versus standard anticoagulation for acute deep vein thrombosis of the lower limb (2021) · Cochrane | RR 2.42 [1.42, 4.12] | 7 studies · 654 participants | Moderate |
Intervention NR Bleeding (early, up to 1 month after treatment) · patients diagnosed with acute DVT Thrombolytic strategies versus standard anticoagulation for acute deep vein thrombosis of the lower limb (2021) · Cochrane | RR 2.45 [1.58, 3.78] | 19 studies · 1943 participants | Moderate |
Intervention NR Post‐thrombotic syndrome (intermediate, 6 months to under 5 years after treatment) · patients diagnosed with acute DVT Thrombolytic strategies versus standard anticoagulation for acute deep vein thrombosis of the lower limb (2021) · Cochrane | RR 0.78 [0.66, 0.93] | 6 studies · 1393 participants | Moderate |
Intervention NR Post‐thrombotic syndrome (late, 5 years · patients diagnosed with acute DVT Thrombolytic strategies versus standard anticoagulation for acute deep vein thrombosis of the lower limb (2021) · Cochrane | RR 0.56 [0.43, 0.73] | 2 studies · 211 participants | Moderate |
Aspirin vs placebo Graft thrombosis (28 days to 18 months) · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | OR 0.4 [0.07, 2.25] | 3 studies · 175 participants | Low |
Dipyridamole vs placebo Duration of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | NR | No studies |
Dipyridamole vs placebo Complications (up to 18 months) · people with ESRD receiving haemodialysis through an arteriovenous graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | 1 study · 42 participants | Low |
Dipyridamole vs placebo Number of related surgical or radiological interventions · people with ESRD receiving haemodialysis through an arteriovenous graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | NR | No studies |
Dipyridamole plus aspirin vs placebo Graft thrombosis (up to 18 months) · people with ESRD receiving haemodialysis through an arteriovenous graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | OR 0.64 [0.16, 2.56] | 1 study · 41 participants | Moderate |
Dipyridamole plus aspirin vs placebo Duration of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | NR | No studies |
Dipyridamole plus aspirin vs placebo Complications (up to 18 months) · people with ESRD receiving haemodialysis through an arteriovenous graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | 1 study · 41 participants | Low |
Dipyridamole plus aspirin vs placebo Number of related surgical or radiological interventions · people with ESRD receiving haemodialysis through an arteriovenous graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | NR | No studies |
Warfarin vs placebo Graft thrombosis (up to 37 months) · people with ESRD receiving haemodialysis through an arteriovenous graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | OR 1.76 [0.78, 3.99] | 1 study · 107 participants | Low |
Warfarin vs placebo Duration of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | NR | No studies |
Warfarin vs placebo Complications (up to 37 months) · people with ESRD receiving haemodialysis through an arteriovenous graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | 1 study · 107 participants | Low |
Aspirin vs placebo Duration of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | NR | No studies |
Warfarin vs placebo Number of related surgical or radiological interventions · people with ESRD receiving haemodialysis through an arteriovenous graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | NR | No studies |
Fish oil vs placebo Graft thrombosis (up to 12 months) · people with ESRD receiving haemodialysis through an arteriovenous graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | OR 0.24 [0.03, 1.95] | 2 studies · 220 participants | Low |
Fish oil vs placebo Duration of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | NR | No studies |
Fish oil vs placebo Complications (up to 12 months) · people with ESRD receiving haemodialysis through an arteriovenous graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | 1 study · 196 participants | Moderate |
Fish oil vs placebo Radiological or surgical intervention (up to 12 months) · people with ESRD receiving haemodialysis through an arteriovenous graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | OR 0.64 [0.36, 1.12] | 1 study · 196 participants | Moderate |
Clopidogrel vs placebo Fistula thrombosis (42 days to 6 months) · people with ESRD receiving haemodialysis through an arteriovenous fistula Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | OR 0.4 [0.13, 1.19] | 2 studies · 959 participants | Moderate |
Clopidogrel vs placebo Duration of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous fistula Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | NR | No studies |
Clopidogrel vs placebo Complication: all bleeding (up to 6 months) · people with ESRD receiving haemodialysis through an arteriovenous fistula Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | OR 1.06 [0.55, 2.03] | 2 studies · 970 participants | Moderate |
Clopidogrel vs placebo Complication: mortality (up to 6 months) · people with ESRD receiving haemodialysis through an arteriovenous fistula Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | OR 1 | 2 studies · 970 participants | Moderate |
Clopidogrel vs placebo Number of related surgical or radiological interventions (42 days) · people with ESRD receiving haemodialysis through an arteriovenous fistula Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | OR 0.69 [0.26, 1.82] | 1 study · 866 participants | Moderate |
Aspirin vs placebo Complications (28 days to 18 months) · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | 3 studies · 175 participants | Low |
Sulphinpyrazone vs placebo Graft thrombosis (up to 3 months) · people with ESRD receiving haemodialysis through an arteriovenous fistula or arteriovenous graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | OR 0.43 [0.03, 5.98] | 1 study · 16 participants | Low |
Sulphinpyrazone vs placebo Duration of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous fistula or arteriovenous graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | NR | No studies |
Sulphinpyrazone vs placebo Complications (up to 3 months) · people with ESRD receiving haemodialysis through an arteriovenous fistula or arteriovenous graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | NR | Low |
Sulphinpyrazone vs placebo Number of related surgical or radiological interventions · people with ESRD receiving haemodialysis through an arteriovenous fistula or arteriovenous graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | NR | No studies |
Glyceryl trinitrate patch vs placebo Fistula failure (6 weeks) · people with ESRD receiving haemodialysis through an arteriovenous fistula Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | OR 1.26 [0.63, 2.54] | 1 study · 167 participants | Moderate |
Glyceryl trinitrate patch vs placebo Duration of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous fistula Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | NR | No studies |
Glyceryl trinitrate patch vs placebo Complications (6 weeks) · people with ESRD receiving haemodialysis through an arteriovenous fistula Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | 1 study · 167 participants | Moderate |
Glyceryl trinitrate patch vs placebo Number of related surgical or radiological interventions · people with ESRD receiving haemodialysis through an arteriovenous fistula Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | NR | No studies |
Aspirin vs placebo Number of related surgical or radiological interventions · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | NR | No studies |
Ticlopidine vs placebo Fistulae thromboses (up to 1 month) · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | OR 0.45 [0.25, 0.82] | 3 studies · 339 participants | Moderate |
Ticlopidine vs placebo Duration of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | NR | No studies |
Ticlopidine vs placebo Complications (up to 1 month) · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | 3 studies · 339 participants | Low |
Ticlopidine vs placebo Number of related surgical or radiological interventions · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | NR | No studies |
Dipyridamole vs placebo Graft thrombosis (up to 18 months) · people with ESRD receiving haemodialysis through an arteriovenous graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | OR 0.46 [0.11, 1.94] | 1 study · 42 participants | Moderate |
Cilostazol vs placebo Initial claudication distance (change in metres) · intermittent claudication Cilostazol for intermittent claudication (2021) · Cochrane | no estimate extracted | 6 studies · 1722 participants | Low |
Cilostazol vs pentoxifylline Absolute claudication distance (change in metres) · intermittent claudication Cilostazol for intermittent claudication (2021) · Cochrane | no estimate extracted | 2 studies · 866 participants | Very low |
Cilostazol vs pentoxifylline Arterial revascularisation · intermittent claudication Cilostazol for intermittent claudication (2021) · Cochrane | no estimate extracted | NR | No studies |
Cilostazol vs pentoxifylline Amputation · intermittent claudication Cilostazol for intermittent claudication (2021) · Cochrane | no estimate extracted | NR | No studies |
Cilostazol vs pentoxifylline Adverse event related to study medication ‐ headache (number of cases) · intermittent claudication Cilostazol for intermittent claudication (2021) · Cochrane | OR 2.2 [1.16, 4.17] | 2 studies · 982 participants | Low |
Cilostazol vs pentoxifylline Cardiovascular event · intermittent claudication Cilostazol for intermittent claudication (2021) · Cochrane | no estimate extracted | NR | No studies |
Cilostazol vs placebo Quality of life (change in points/ percentage; COM, SF‐36, VascuQol, WIQ) · intermittent claudication Cilostazol for intermittent claudication (2021) · Cochrane | no estimate extracted | 4 studies · 1163 participants | Low |
Cilostazol vs placebo Absolute claudication distance (change in metres) · intermittent claudication Cilostazol for intermittent claudication (2021) · Cochrane | no estimate extracted | 8 studies · 2360 participants | Very low |
Cilostazol vs placebo Arterial revascularisation (number of cases) · intermittent claudication Cilostazol for intermittent claudication (2021) · Cochrane | OR 0.16 [0.01, 4.07] | 1 study · 516 participants | Very low |